Soliqua 100/33
Payments companies reported to CMS as associated with Soliqua 100/33. "Associated with" is CMS's wording: it links a payment to a product without saying the money was spent on it.
By year
Payments reported as associated with Soliqua 100/33, per program year, as reported to CMS.
Who makes it
Specialties most often involved
Where the associated payments went, by the receiving clinician's specialty.
Clinicians most associated with Soliqua 100/33
These are the largest totals companies reported as associated with Soliqua 100/33. They are typically speaking or consulting arrangements, which companies must report by law; appearing here is not evidence of anything improper.
| Clinician | Location | Specialty | Associated payments (2023-2025) |
|---|---|---|---|
| Julio Rosenstock | Dallas, TX | Endocrinology, Diabetes & Metabolism | $224,789.48 |
| Juan Frias | San Diego, CA | Endocrinology, Diabetes & Metabolism | $46,319.60 |
| Yehuda Handelsman | Tarzana, CA | Endocrinology, Diabetes & Metabolism | $43,492.42 |
| Nawras Makhsida | Randolph, NJ | Endocrinology, Diabetes & Metabolism | $20,534.04 |
| Emily Sims | Indianapolis, IN | Pediatric Endocrinology | $13,419.45 |
| Thomas Martens | Brooklyn Center, MN | Internal Medicine | $12,868.91 |
| Jeremy Pettus | San Diego, CA | Endocrinology, Diabetes & Metabolism | $11,962.12 |
| Jay Skyler | Miami, FL | Endocrinology, Diabetes & Metabolism | $11,424.80 |
| Viralkumar Shah | Aurora, CO | Endocrinology, Diabetes & Metabolism | $10,895.12 |
| Kimberly Simmons | Aurora, CO | Pediatric Endocrinology | $9,731.79 |
Prescribed Soliqua 100/33?
See what its makers reported for your doctor. Two steps, private, no account.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.